Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma

Francesco Lauria, Michele Baccarani, Mauro Fiacchini, Marco Gobbi, Sante Tura

Research output: Contribution to journalArticle

Abstract

Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalEuropean Journal of Cancer (1965)
Volume11
Issue number5
DOIs
Publication statusPublished - 1975

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Vincristine
Methotrexate
Non-Hodgkin's Lymphoma
Cyclophosphamide
B-Cell Chronic Lymphocytic Leukemia
Alkylating Agents
Combination Drug Therapy
Pharmaceutical Preparations
Cell Cycle
Outpatients

ASJC Scopus subject areas

  • Oncology

Cite this

Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma. / Lauria, Francesco; Baccarani, Michele; Fiacchini, Mauro; Gobbi, Marco; Tura, Sante.

In: European Journal of Cancer (1965), Vol. 11, No. 5, 1975, p. 343-349.

Research output: Contribution to journalArticle

Lauria, Francesco ; Baccarani, Michele ; Fiacchini, Mauro ; Gobbi, Marco ; Tura, Sante. / Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma. In: European Journal of Cancer (1965). 1975 ; Vol. 11, No. 5. pp. 343-349.
@article{d078c72869fe4be5b1f543db3fd9037a,
title = "Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma",
abstract = "Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.",
author = "Francesco Lauria and Michele Baccarani and Mauro Fiacchini and Marco Gobbi and Sante Tura",
year = "1975",
doi = "10.1016/0014-2964(75)90062-6",
language = "English",
volume = "11",
pages = "343--349",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma

AU - Lauria, Francesco

AU - Baccarani, Michele

AU - Fiacchini, Mauro

AU - Gobbi, Marco

AU - Tura, Sante

PY - 1975

Y1 - 1975

N2 - Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.

AB - Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0016684984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016684984&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(75)90062-6

DO - 10.1016/0014-2964(75)90062-6

M3 - Article

C2 - 1098915

AN - SCOPUS:0016684984

VL - 11

SP - 343

EP - 349

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 5

ER -